CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Price, Forecast & Analysis
USA - NASDAQ:CYCC - US23254L8019 - Common Stock
CYCC Key Statistics, Chart & Performance
The current stock price of CYCC is 6.365 USD. In the past month the price decreased by -28.48%. In the past year, price decreased by -97.37%.
CYCC Latest News, Press Relases and Analysis
CYCC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.18 | 386.95B | ||
| AMGN | AMGEN INC | 14.43 | 169.90B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.98 | 106.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.37 | 68.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 863.71 | 57.74B | ||
| INSM | INSMED INC | N/A | 39.25B | ||
| NTRA | NATERA INC | N/A | 27.24B | ||
| BIIB | BIOGEN INC | 9.36 | 22.98B | ||
| INCY | INCYTE CORP | 16.39 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 37.03 | 15.35B |
Related stock screener links
About CYCC
Company Profile
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
Company Info
CYCLACEL PHARMACEUTICALS INC
200 Connell Dr Ste 1500
Berkeley Heights NEW JERSEY 07922 US
CEO: Spiro Rombotis
Employees: 12
Phone: 19085177330
CYCLACEL PHARMACEUTICALS INC / CYCC FAQ
What does CYCC do?
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
What is the stock price of CYCLACEL PHARMACEUTICALS INC today?
The current stock price of CYCC is 6.365 USD. The price decreased by -5.98% in the last trading session.
Does CYCLACEL PHARMACEUTICALS INC pay dividends?
CYCC does not pay a dividend.
How is the ChartMill rating for CYCLACEL PHARMACEUTICALS INC?
CYCC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for CYCLACEL PHARMACEUTICALS INC?
CYCLACEL PHARMACEUTICALS INC (CYCC) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of CYCC stock?
CYCLACEL PHARMACEUTICALS INC (CYCC) has a market capitalization of 14.26M USD. This makes CYCC a Nano Cap stock.
When does CYCLACEL PHARMACEUTICALS INC (CYCC) report earnings?
CYCLACEL PHARMACEUTICALS INC (CYCC) will report earnings on 2025-11-10.
CYCC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CYCC. When comparing the yearly performance of all stocks, CYCC is a bad performer in the overall market: 96.83% of all stocks are doing better.
CYCC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYCC. The financial health of CYCC is average, but there are quite some concerns on its profitability.
CYCC Financial Highlights
Over the last trailing twelve months CYCC reported a non-GAAP Earnings per Share(EPS) of -122.02. The EPS increased by 96.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.06% | ||
| ROE | -177.03% | ||
| Debt/Equity | 0 |
CYCC Forecast & Estimates
For the next year, analysts expect an EPS growth of 39.49% and a revenue growth 88.68% for CYCC